Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies

Journal of the American Academy of Dermatology

Volumn 73, Issue 1, 2015, Pages 62-69

  Elewski, Boni E ^a   Aly, Raza ^b   Baldwin, Sheryl L ^c   González Soto, Remigio F ^d   Rich, Phoebe ^e   Weisfeld, Max ^f   Wiltz, Hector ^g   Zane, Lee T ^d   Pollak, Richard ^h  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PFIZER INC   (United States)

^d Centro de Dermatologia de Monterrey   (Mexico)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f Hamilton Foot Care   (United States)

^g FXM Research Corp   (United States)

^h Endeavor Clinical Trials PA   (United States)

Author keywords

antifungal agents; arthrodermataceae; nails; onychomycosis; randomized controlled trial; tavaborole

Indexed keywords

TAVABOROLE; ANTIFUNGAL AGENT; BORON DERIVATIVE; FUSED HETEROCYCLIC RINGS;

ADULT; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE REACTION; ARTICLE; CONTROLLED STUDY; DERMATITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMATOMA; HUMAN; HYPERTENSION; INCIDENCE; INFLUENZA; INGROWN NAIL; MAJOR CLINICAL STUDY; MALE; MEDICAL PHOTOGRAPHY; MULTICENTER STUDY; MUSCLE STRAIN; MYCOLOGY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK ASSESSMENT; SKIN EXFOLIATION; TINEA PEDIS; TOENAIL ONYCHOMYCOSIS; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; AGED; CLINICAL TRIAL; FOOT DERMATOSES; MIDDLE AGED; ONYCHOMYCOSIS; TOPICAL DRUG ADMINISTRATION; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; BORON COMPOUNDS; DOUBLE-BLIND METHOD; FEMALE; FOOT DERMATOSES; HUMANS; MALE; MIDDLE AGED; ONYCHOMYCOSIS; YOUNG ADULT;

EID: 84937970128     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.04.010     Document Type: Article

References (10)

1. Kerydin [package insert] 2014 Anacor Pharmaceuticals, Inc Palo Alto, CA
2. Lamisil [package insert] 2013 Novartis Pharmaceuticals Corp East Hanover, NJ
3. Sporanox capsules [package insert] 2012 Janssen Pharmaceuticals, Inc Titusville, NJ
4. Penlac [package insert] 2006 Dermik Laboratories, a division of Sanofi-Aventis US LLC Bridgewater, NJ
5. F.L. Rock, W. Mao, A. Yaremchuk, and et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site Science 316 2007 1759 1761
6. O. Barak, and D.S. Loo AN-2690, a novel antifungal for the topical treatment of onychomycosis Curr Opin Investig Drugs 8 2007 662 668
7. X. Hui, S.J. Baker, R.C. Wester, and et al. In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate J Pharm Sci 96 2007 2622 2631
8. Hold KM, Sanders V, Bu W, et al. Nail penetration and nail concentration of AN2690, a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis. Poster presented at the Annual Meeting of the American Association of Pharmaceutical Scientists; October 29-November 2, 2006; San Antonio, TX.
9. Zane LT, Pollak RA. Safety and efficacy of tavaborole (formerly AN2690), a novel boron-based molecule, in phase 2 trials for the topical treatment of toenail onychomycosis. Poster presented at the Annual Scientific Meeting of the American Podiatric Medical Association; August 16-19, 2012; Washington, DC.
10. B.E. Elewski, and A. Tosti Tavaborole for the treatment of onychomycosis Expert Opin Pharmacother 15 2014 1439 1448